Oncology Product Candidates
Our key product candidates include:
BLP25 Liposome Vaccine
BLP25 Liposome Vaccine (L-BLP25, StimuvaxR) is an investigational therapeutic cancer immunotherapy designed to stimulate the body's immune system to target cancer cells expressing MUC1. EMD Serono is currently investigating the use of BLP25 liposome vaccine in a randomized double-blind, placebo-controlled Phase III trial (START) that will enroll more than 1,300 patients in approximately 30 countries with unresectable stage III non-small cell lung cancer (NSCLC).
BLP25 Liposome Vaccine (L-BLP25, StimuvaxR) is an investigational therapeutic cancer immunotherapy designed to stimulate the body's immune system to target cancer cells expressing MUC1. EMD Serono is currently investigating the use of BLP25 liposome vaccine in a randomized double-blind, placebo-controlled Phase III trial (START) that will enroll more than 1,300 patients in approximately 30 countries with unresectable stage III non-small cell lung cancer (NSCLC).
Cilengitide
Cilengitide is an investigational agent in a new class of targeted anti-cancer therapies called integrin inhibitors. Cilengitide, combined with the standard of care (radiotherapy and temozolomide) is currently being investigated in a Phase III trial (CENTRIC) in patients with newly diagnosed glioblastoma. The US National Cancer Institute (NCI) is also sponsoring a number of clinical trials for the development of cilengitide.
Cilengitide is an investigational agent in a new class of targeted anti-cancer therapies called integrin inhibitors. Cilengitide, combined with the standard of care (radiotherapy and temozolomide) is currently being investigated in a Phase III trial (CENTRIC) in patients with newly diagnosed glioblastoma. The US National Cancer Institute (NCI) is also sponsoring a number of clinical trials for the development of cilengitide.
DOWNLOAD
